A Review of Botulinum Toxcin Use for Chronic Pelvic Pain Syndrome

Gottsch, Henry P.; Yang, Claire C.; Berger, Richard E.

doi:10.1007/s11934-010-0118-4

Cited by 6 publications

(3 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These studies used different routes of injections (transurethral, transrectal and transperineal), different doses of BTX-A (30-200 U) and different outcome variables (uroflowmetry, visual pain analogue score, pelvic floor tenderness, Global Response Assessment and total CPSI) [24][25][26][27][28][29].…”

Section: Discussionmentioning

confidence: 99%

195 Intraprostatic Injection of Botulinum Toxin-A in Patients with Refractory Chronic Pelvic Pain Syndrome: The Transurethral vs. Transrectal Approach

ElEnen

Abou

et al. 2018

The Journal of Sexual Medicine

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

195 Intraprostatic Injection of Botulinum Toxin-A in Patients with Refractory Chronic Pelvic Pain Syndrome: The Transurethral vs. Transrectal Approach

ElEnen

Abou

et al. 2018

The Journal of Sexual Medicine

View full text Add to dashboard Cite

“…To our knowledge there are few clinical trials evaluating the role of BTX-A in patients with CP/CPPS, and only one was designed as a controlled study. These studies used different routes of injections (transurethral, transrectal and transperineal), different doses of BTX-A (30–200 U) and different outcome variables (uroflowmetry, visual pain analogue score, pelvic floor tenderness, Global Response Assessment and total CPSI) [24–29] .…”

Section: Discussionmentioning

confidence: 99%

Intraprostatic injection of botulinum toxin-A in patients with refractory chronic pelvic pain syndrome: The transurethral vs. transrectal approach

El-Enen

Abou-Farha

El-Abd

et al. 2015

Arab Journal of Urology

View full text Add to dashboard Cite

ObjectiveTo evaluate the outcome of an intraprostatic injection of botulinum toxin-A (BTX-A) in men with refractory chronic prostatitis-associated chronic pelvic-pain syndrome (CP/CPPS) and to compare the efficacy of the transurethral and transrectal routes.Patients and methodsIn an uncontrolled randomised clinical trial conducted in men with refractory CP/CPPS, the patients were classified into two groups according to the route of BTX-A injection; transurethral (group 1, 28 patients) and transrectal ultrasonography-guided (group 2, 35 patients). The chronic prostatitis symptom index (CPSI), maximum urinary flow rate (Qmax) and white blood cell (WBC) count in expressed prostatic secretion (EPS) were measured before and at 3, 6 and 12 months after the injection. A significant clinical improvement (SCI, defined as a reduction of 4 points or a 25% decrease in total CPSI score) was correlated with patient age, prostate volume and symptom duration.ResultsIn group 1, the pain and quality-of-life domain scores improved, but statistically significantly only at 6 months. The voiding score improved at all follow-up visits. In group 2 there was a significant improvement in all the CPSI domain scores at all follow-up visits, except for pain, which was insignificantly improved by 12 months. The SCI ratings in groups 1 and 2 were 36%, 79% and 57%, and 49%, 89% and 74% in group 2 at the three follow-up visits, respectively. The Qmax was significantly improved in both groups during the follow-up (except at 12 months in group 1). There was a significant reduction in the mean WBC count in the EPS in patients with inflammatory prostatitis. Both prostate volume and symptom duration were significantly associated with a lower SCI rating.ConclusionBTX-A is an available treatment option for patients with refractory CP/CPPS. It is more effective in patients with a small prostate and short symptom duration. The transrectal route provided better results than the transurethral route. More prospective longer term studies are needed.

show abstract

“…There have been no large, randomized trials, however, that have demonstrated statistically significant improvement or durability. Because of the favorable results in women with IC/PBS and the potentially numerous targets for botulinum in UCPP in men, it may play an important role in a "polytherapeutic approach" [38].…”

Section: Management Of Lower Urinary Tract Symptoms Associated With Umentioning

confidence: 99%

Lower Urinary Tract Symptoms Associated with Male Urologic Pelvic Pain Syndrome

Potts

2011

Curr Bladder Dysfunct Rep

View full text Add to dashboard Cite

A common urologic diagnosis in men, urologic chronic pelvic pain (UCPP) is often associated with bothersome lower urinary tract symptoms (LUTS), which contribute to the diminished quality of life observed in these patients. The differential diagnosis of LUTS as a separate entity should be considered during evaluation of UCPP patients to exclude other urologic or neurological conditions. However, most patients can be afforded improvement of LUTS as they receive appropriate therapy for UCPP.

show abstract

A Review of Botulinum Toxcin Use for Chronic Pelvic Pain Syndrome

Cited by 6 publications

References 48 publications

195 Intraprostatic Injection of Botulinum Toxin-A in Patients with Refractory Chronic Pelvic Pain Syndrome: The Transurethral vs. Transrectal Approach

195 Intraprostatic Injection of Botulinum Toxin-A in Patients with Refractory Chronic Pelvic Pain Syndrome: The Transurethral vs. Transrectal Approach

Intraprostatic injection of botulinum toxin-A in patients with refractory chronic pelvic pain syndrome: The transurethral vs. transrectal approach

Lower Urinary Tract Symptoms Associated with Male Urologic Pelvic Pain Syndrome

Contact Info

Product

Resources

About